Long-term human albumin therapy failed to significantly improve long-term survival outcomes in cirrhotic patients with acute decompensation and ascites, the phase III randomized PRECIOSA trial showed.

EPO grants Sonnet EU Patent No. EP3583125 B1 for Fully Human Albumin Binding (FHAB®) domain fusion proteins, expanding global IP protection. Sonnet BioTherapeutics Holdings, Inc. announced that the ...

JUNCTION CITY, Kan.--(BUSINESS WIRE)--InVitria, a leading developer of recombinant, chemically defined components for biomanufacturing, has announced the launch of Optibumin® 25, the first and only ...

Albumin is a major prognostic factor for patients with advanced liver disease, dependent on its concentration and biological activity. This study aimed to improve the method of active albumin ...

Albumin is the most common protein in the blood, a vital molecule produced by the liver that helps maintain fluid balance and ...

The connection between perturbations in BBB barrier function and damage to the astrocyte network and its functions arises from BBB damage, leading to the extravasation of albumin. In the physiological ...

An A/G ratio is a blood test that compares the amount of albumin and globulin in your blood. A normal A/G ratio is between 1.1 and 2.5. A low A/G ratio may be due to kidney disease, liver disease, ...

Optibumin® 25 in 100 mL bags: The first recombinant 25% human serum albumin solution designed for closed-system biomanufacturing. Recombinant alternative to plasma-derived HSA enables safer, scalable, ...